NEW YORK – BostonGene will conduct genomic analysis to identify best responders to Transgene's investigational, bespoke cancer vaccine, TG4050, within two ongoing trials, the companies said on Tuesday.
NEW YORK – BostonGene will conduct genomic analysis to identify best responders to Transgene's investigational, bespoke cancer vaccine, TG4050, within two ongoing trials, the companies said on Tuesday.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.